Introduction {#S1}
============

The biological functions of macrophages are diverse and not only limited to their role as the first line of defense during innate immune response. In addition to their protective role against infections, the known roles of macrophages have expanded in recent years, and their involvement in organ development, tissue homeostasis, and metabolic dysfunctions, such as diabetes and obesity, are increasingly appreciated. Cancer is another area in which macrophages have emerged as a crucial player in the creation of a tumor microenvironment that supports tumor growth and metastasis, in opposition to their traditional role as an innate immune cell, whose function is to eliminate cancer cells ([@B1]). Therefore, understanding the signaling pathway(s) governing the development, differentiation, activation, deactivation, proliferation, and cell death of macrophages in the context of tumorigenesis is expected to reveal novel strategies for targeting cancer growth more effectively.

The critical functions of the evolutionarily well-conserved Notch signaling pathway in myeloid lineage cell development and, in particular, monocyte/macrophage development are well recognized and have been reviewed extensively elsewhere ([@B2], [@B3]). Recent evidence, using state of the art technologies, revealed better defined subsets of circulating monocytes and the uniqueness and the origin of tissue-resident macrophages (TRMs). This new insight reignited the excitement in the field of macrophage biology. In addition, these studies cast new light and controversy over the origin of macrophages found in tumors, called tumor-associated macrophages (TAMs), and the involvement of TAMs in cancer progression and suppression ([@B4], [@B5]). Within tumors of various origins, macrophages have been observed to accumulate in large numbers and exhibit unique combinations of activated phenotypes ([@B6]). In general, TAMs in large quantities are associated with poor disease prognosis, partly by promoting tumor growth, dampening immune responses, and inducing angiogenesis and metastasis ([@B7], [@B8]). Together with the recent advances in the understanding of the roles, Notch signaling plays in the activation and regulation of the immune effector functions of macrophages and in TAMs, these observations have led to the conclusion that Notch signaling is one of the candidate pathways to be manipulated to enhance the host anti-tumor response. In this review, we summarize the current knowledge of the involvement of Notch signaling in macrophage activation, with an emphasis on its role(s) in TAMs. We also discuss the cross-talk among macrophages, tumor cells, and other cells associated with the tumor microenvironment and the potential utility and challenges in manipulating Notch signaling in TAMs for tumor suppression in ways that are beneficial to the host.

Notch Signaling in Macrophage Activation and Function {#S1-1}
-----------------------------------------------------

The biological functions of macrophages are multi-faceted depending on the external microenvironment, and some functions may be contradictory or opposing to others. For example, during infection or tissue injury, macrophages sense danger *via* various receptors, actively eliminate the source of danger by phagocytosis and chemical mediators, and trigger inflammation by producing inflammatory cytokines to alert other immune cells. After the elimination phase, wounds are healed mainly by anti-inflammatory wound-healing macrophages ([@B9]). The contradictory inflammatory and anti-inflammatory microenvironments are conducive to driving macrophage activation into two opposite functional spectra. The most simplistic view of macrophage effector functions divides activated macrophages into pro-inflammatory macrophages, in which macrophages are activated by pathogen-associated molecular patterns (PAMPs) and/or inflammatory cytokines. In contrast, anti-inflammatory macrophages, activated by IL-4/IL-13, represent a wound-healing and immunosuppressive phenotype ([@B10]). However, more detailed characterization and studies in various *in vivo* models have revealed a more complicated view of macrophage effector phenotypes that are often observed in an *in vivo* setting ([@B11]). Thus, the narrow concept of pro- vs. anti-inflammatory macrophages may be oversimplified, and the presence of various hybrid phenotypes of macrophages has been described ([@B11]). Some of the genes uniquely expressed in pro- or anti-inflammatory macrophages are summarized in Table [1](#T1){ref-type="table"} ([@B12], [@B13]).

###### 

Expression profiles of Notch ligands and receptors and some stage-specific makers in tumor-associated macrophages (TAMs).

  Notch receptors/ligands or surface markers related to TAMs   Pro-inflammatory macrophages          Anti-inflammatory macrophages         Differentiation stages of TAMs based on study by Franklin et al. ([@B14])                                                       
  ------------------------------------------------------------ ------------------------------------- ------------------------------------- --------------------------------------------------------------------------- ------ ------ ------------------------------------- -------------------------------------
  CCR2                                                         \+                                    −                                     \+                                                                          \+     \+     \+                                    \+
  Ly6C                                                         \+                                    −                                     \+                                                                          −      −      −                                     −
  CD11c                                                                                                                                    −                                                                           \+     \+     \+                                    \+
  MHCII                                                        \+                                    \+                                    −                                                                           −      \+     \+                                    \+
  CD11b                                                        \+                                    \+[^a^](#tfn1){ref-type="table-fn"}   high                                                                        high   high   low                                   low
  Vascular cell adhesion molecule1                                                                                                         −                                                                           −      −      −                                     \+^b^
  CD38                                                         \+                                    −                                                                                                                                                                     
  Erg2                                                         −                                     \+[^c^](#tfn3){ref-type="table-fn"}                                                                                                                                   
                                                                                                                                                                                                                                                                           
  Notch receptors                                                                                                                                                                                                                                                          
  Notch1                                                       \+                                    \+                                                                                                                \+     \+     \+                                    \+
  Notch2                                                       \+[^d^](#tfn4){ref-type="table-fn"}   \+                                                                                                                \+     \+     \+[^e^](#tfn5){ref-type="table-fn"}   \+
  Notch3                                                       \+                                                                                                                                                                                                          
  Notch4                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                           
  Notch ligands                                                                                                                                                                                                                                                            
  Jagged1                                                      \+                                                                                                                                                                                                          
  Jagged2                                                                                                                                                                                                                                                                  
  Dll1                                                         \+                                    \+                                                                                                                                                                    \+
  Dll3                                                                                                                                                                                                                                                                     
  Dll4                                                         \+                                    \+[^g^](#tfn7){ref-type="table-fn"}                                                                                                                                   \+[^f^](#tfn6){ref-type="table-fn"}

*^a^Italiani and Boraschi ([@B12]) provide reviews on murine blood monocyte subsets based on Ly6C expression and their functions in inflammation and tissue repair*.

*^b^Franklin et al. ([@B14]) propose TAM markers found in a breast cancer mouse model*.

*^c^Jablonski et al. ([@B13]) propose novel markers of M(LPS + IFNγ) and M(IL-4) (CD38 and Erg2) based on gene expression profiles that can exclusively distinguish M(LPS + IFNγ) from M(IL-4)*.

*^d^Palaga et al. ([@B15]) report the gene expression profile of LPS-stimulated RAW264.7 macrophages*.

*^e^Ishifune et al. ([@B16]) report that Notch receptors are required for CD11c^+^ CX3CR1^+^ macrophage (found in the luminal bed of the small intestine) differentiation, thereby suggesting that Notch1 and Notch2, but not Notch3 may be required for TAM differentiation as TAM is also CD11c^+^*.

*^f^Wang et al. ([@B17]) report the Notch gene expression profile in anti-inflammatory-like macrophages isolated from tumors*.

*^g^Bansal et al. ([@B18]) report Notch profiles in RAW264.7 M(LPS + IFNγ) and M(IL-4 + IL-13)*.

To avoid oversimplification and confusion over macrophage effector phenotypes, this review will adopt the macrophage nomenclatures proposed by Murray et al. to describe specific macrophage subsets based on the stimuli and effector functions described in each referred study ([@B19]). In some instances, where the stimuli were not identified, the microenvironments in which macrophages were described will be used.

Initial reports generally found that Notch signaling primarily operates in macrophages that are activated toward inflammatory functions such as in lipopolysaccharide (LPS)-activated macrophages M(LPS) or LPS in combination with IFNγ M(LPS + IFNγ) ([@B15], [@B20], [@B21]). Subsequent findings in various pathophysiological conditions also indicated the involvement of Notch signaling in activation and effector functions of pro-inflammatory macrophages ([@B3]). Notch signaling, therefore, favors inflammatory macrophages, and when the Notch signaling pathway is pharmacologically or genetically blocked, some of the key pro-inflammatory functions are compromised, including the decrease in the production of pro-inflammatory cytokines, such as IL-6, and the reduction in nitric oxide production ([@B15], [@B22]). To this end, Notch signaling is reported to directly or indirectly influence pro-inflammatory effector functions. Notch signaling can directly regulate transcription of some of the inflammation-induced signature genes, such as *il6, il12b*, and *nos2* ([@B23]--[@B25]). Using *Rbpj*-deficient mice, Xu et al. demonstrated that canonical Notch signaling tips the effector phenotypes toward inflammatory ones by directly influencing the transcription of a transcription factor IRF8 ([@B22]). In addition, Notch signaling also indirectly regulates pro-inflammatory phenotypes through a cross-talk with other signaling pathways, such as NF-κB and mitogen-activated protein kinases ([@B15], [@B20]). Interestingly, metabolic analysis found that Notch signaling supports inflammatory macrophage phenotypes by reprograming mitochondrial metabolism toward oxidative phosphorylation ([@B25]). Abrogating Notch signaling in myeloid lineage cells attenuated inflammation in a mouse model of alcoholic steatohepatitis and reduced the severity of endotoxin-induced hepatitis ([@B25]). All evidence, therefore, points to a critical role of Notch signaling in macrophage activation toward pro-inflammatory phenotypes in a canonical Notch signaling-dependent (intracellular Notch and CSL/RBP-Jκ-dependent) manner. The question remains whether inhibition of Notch signaling under an inflammatory microenvironment can switch macrophages toward the opposite phenotype, such as anti-inflammatory functions, or whether a lack of Notch signaling only dampens the inflammatory response without directing the macrophages toward other effector phenotypes.

Is Notch signaling dispensable for other types of macrophage effector functions? In macrophages treated with IL-4/IL-13 M(IL-4/IL-13), which normally induces anti-inflammatory macrophages. Notch signaling was long considered to be irrelevant; however, an indicator that Notch signaling is activated in the form of cleaved Notch1 was observed in this condition, albeit with different kinetics than those reported in M(LPS + IFNγ) ([@B26]). More importantly, in macrophages with targeted deletion of *Rbpj*, CSL/RBP-Jκ, possibly through canonical Notch signaling, was found to be required for activation of M(IL-4) or M(chitin), including the expression of the gene signature associated with M(IL-4), such as *Arg1* expression ([@B27]). This involvement was independent of STAT6, C/EBPβ, and IRF8. In addition, our observation revealed that Notch signaling functions in macrophages activated by PAMPs in the presence of immune complexes and LPS M(LPS + Ic), which predominantly produce high amounts of IL-10 and low levels of IL-12 to function in dampening the immune response ([@B28], [@B29]). Together, these data indicate the need for re-thinking the roles that Notch signaling plays in macrophage activation. Notch signaling may be involved in various types of macrophage activation in a context-dependent manner. Whether Notch signaling functions as an instructor or a signal amplifier during macrophage activation remains to be determined, but this feature is similar to what has been postulated for the involvement of Notch signaling in the polarization of helper T cells ([@B30]).

Notch Receptors and Ligands During Macrophage Activation {#S1-2}
--------------------------------------------------------

Four Notch receptors and five Notch ligands have been identified thus far. Differences in signals sent *via* different combinations of ligand--receptor interactions have long been suspected. For example, two ligands, Dll1 and Dll4, send different signals through the same receptor, Notch1, that are either pulsatile or sustained, thereby inducing different cell fates ([@B31]). During macrophage activation, various Notch receptors and ligands have been detected (Table [1](#T1){ref-type="table"}). All Notch receptors, except for Notch4, are expressed in pro-inflammatory M(LPS) or M(LPS + IFNγ) ([@B15]). Notch3 is selectively upregulated in pro-inflammatory macrophages, such as in M(LPS) and M(LDL) ([@B21]). Notch1 and Notch2 are required for differentiation of CD11c^+^ CX3CR1^+^ macrophage subset in the small intestine ([@B16]). Similarly, Jagged1, Dll1, and Dll4 are detected in pro-inflammatory macrophages ([@B18]). In M(LPS), Foldi et al. reported that Jagged1 is the ligand responsible for autoamplification of Notch signaling in pro-inflammatory macrophages ([@B32]). The importance of the Notch-Dll4 axis in pro-inflammatory macrophages was highlighted in a study using blocking antibodies against Dll4. The results revealed that the anti-Dll4 antibody reduced pro-inflammatory macrophage accumulation in inflammatory lesions and attenuated atherosclerosis and metabolic disease ([@B33]). Furthermore, during influenza infection, Dll1 expression on macrophages is crucial for dictating the effective anti-viral responses of CD4 and CD8 T cells ([@B34]). Nevertheless, knowledge of the effect of specific combinations of Notch receptors and ligands on macrophage activation is still limited, and requires each receptor and ligand to be specifically blocked to evaluate the relevance of different interaction pairs.

Origins and Functions of TAMs {#S1-3}
-----------------------------

In solid tumors, TAMs are a dominant cell type in tumor tissues of various origins, often second to the tumor cells themselves ([@B35]). This observation leads to the obvious questions of where these TAMs originate and what are their functions in tumors. There are two potential sources of TAMs. TAMs can develop from newly recruited monocytes from circulation or be derived from TRMs. These sources are not mutually exclusive and depend mainly on the tumor type ([@B5]). In a breast cancer model, newly recruited monocytes differentiated to become TAMs, while in brain tumors, both blood-derived monocytes and resident microglia cells contributed to the TAM population ([@B14], [@B36]). When TAMs arise from monocytes recruited from circulation, tumor cells need to secrete factor(s) that trigger the migration of monocytes to the tumor sites (Figure [1](#F1){ref-type="fig"}).

![Involvement of Notch signaling during tumor-associated macrophage (TAM) differentiation and tumor growth. Tumor cells recruit monocytes from circulation by secreting chemotactic factors and inflammatory cytokines. Notch signaling may be required for terminally differentiated TAMs. Within the tumor microenvironment, newly recruited monocytes are conditioned to become pro-inflammatory or anti-inflammatory TAMs *via* the cytokine milieu and possibly the canonical Notch signaling ([@B14]). Tissue-resident macrophages may also contribute to tumor growth by changing to TAMs. TAMs support tumor growth directly by secreted cytokines and growth factors, and indirectly by affecting T-cell response against the tumor ([@B37]). The pro-tumoral function can be Notch signaling dependent or independent. Cancer-associated fibroblasts (CAFs) may also cross-talk with TAMs *via* Notch signaling ([@B38]).](fimmu-09-00652-g001){#F1}

Macrophage phenotypes, in general, are considered highly plastic and can change depending on the microenvironment, and this may also be true for the phenotypes of TAMs in the tumor microenvironment ([@B10]). In one study, human breast cancer cells skewed TAMs toward an anti-inflammatory phenotype partly by secretion of M-CSF ([@B39]). In an *in vivo* model of BALB/c 4T1 mammary carcinoma, the tumor microenvironment condition encouraged monocyte precursors to differentiate into diverse TAM subsets with either pro- or anti-inflammatory phenotypes ([@B40]). Furthermore, studies in renal cell carcinoma have shown mixed pro- and anti-inflammatory phenotypes of TAMs ([@B41]). These observations indicate that there are variations in TAM phenotype that depend on the type of tumors and that the activation of TAMs is highly complex and context-dependent.

Notch Signaling and TAMs {#S1-4}
------------------------

In TAMs, Notch1 and 2 have been detected in breast cancer model, while Dll1 and Dll4 have been detected in a lung cancer model (Table [1](#T1){ref-type="table"}) ([@B14], [@B17]). Jagged1 expression in a breast cancer cell line was shown to modulate TAM differentiation resulting in anti-inflammatory and IL-10-producing TAMs ([@B42]). In human cancer, evidence is still lacking regarding the expression profiles of Notch receptors and ligands in TAMs associated with different types of cancer. Recent study of head and neck head and neck squamous cell carcinoma, increasing Notch1 level is associated with CD68^+^/CD163^+^ TAMs, indirectly suggest the link between Notch signaling and TAMs ([@B43]). Knowing the expression profiles of Notch receptors and ligands in TAMs and the importance of the signals that they send will provide better targets for intervention.

Notch Signaling and Migrations of Monocytes and Differentiation Into TAMs {#S1-5}
-------------------------------------------------------------------------

For monocyte-derived TAMs, the presence of TAMs begins with the recruitment of blood monocytes/macrophages to the tumor microenvironment through newly formed blood vessels around the solid tumor ([@B14], [@B44]). Diverse chemokines, i.e., CCL2 (MCP-1), CCL5 (RANTES), CCL7 (MCP-3), CXCL8 (IL-8), and CXCL12 (SDF1), released by tumor cells induce migration, differentiation, and survival of tumor-infiltrating myeloid cells ([@B45], [@B46]). The chemokine receptor CCR2 has been a subject of intense study as a key molecule of monocyte recruitment into tumors. An *in vitro* study revealed that GM-CSF-induced macrophages M(GC) showed higher CCR2 expression than their M-CSF-induced counterparts M(MC). After CCL2 stimulation, M(GC) exhibited enhanced LPS-mediated IL-10 production, indicating an anti-inflammatory role. These phenomena were confirmed by an *in vivo* study in which *Ccr2*-deficient bone marrow-derived macrophages displayed profiles indicative of inflammatory macrophages ([@B47]). In the MMTV-PyMT mammary tumor model, a decrease in the number of TAMs in the tumor site was observed in *Ccr2*-null background animals, suggesting the importance of CCR2/CCL2 signaling in the recruitment of TAMs to tumor sites ([@B14]). Further investigation revealed that the deletion of *Rbpj* in macrophages results in loss of CCR2 and TAM markers, suggesting a cross-talk between canonical Notch signaling and the CCR2/CCL2 signaling pathway in TAMs in the tumor microenvironment. One can speculate that in the early phase, monocytes are recruited to the tumor site in a CCR2-dependent manner and perhaps begin to encourage activation toward an inflammatory phenotype, but tumor cells educate these cells by creating a tumor microenvironment that re-directs them toward a tumor-friendly phenotype in a later phase of tumor growth (Figure [1](#F1){ref-type="fig"}). In fact, a gradual increase in M(IL-4)-associated markers such as a high level of CD206 expression and low or no MHC Class II molecule expression has been reported in TAMs in a mouse colon cancer model and in human cancer samples ([@B37]). Interestingly, expression of the immune checkpoint receptor, programmed cell death protein 1 (PD1), was significantly increased in CD206^+^ TAMs compared to the expression in TAMs negative for CD206.

In basal-like breast cancer, tumor cells secrete both CCL2 and IL-1β in a Notch-dependent manner, and the secreted cytokine/chemokines, in turn, recruit monocytes to the tumor site ([@B48]). In this case, canonical Notch signaling directly regulates the expression of CCL2 and IL-1β, leading to the adhesion of monocytes to blood vessel and extravasation to migrate toward tumor tissue. CCL2 can be produced by bone marrow-derived stromal cells or tumor cells, while tumor cells produce IL-1β ([@B49]). Once monocytes are recruited, tumor microenvironments train/educate monocytes to differentiate to become TAMs with a pro-tumor phenotype that can function to support tumor growth and metastasis ([@B5]). In this breast cancer model, TAMs interact with cancer cells *via* TGFβ to potentiate the expression of Jagged1, one of the Notch ligands ([@B48]). The Notch/Jagged1 positive feedback loop amplifies cytokine/chemokine secretion leading to more TAM recruitment. In an animal model of breast cancer using MMTV-PyMT mice, Franklin et al. showed conclusively that TAMs are recruited from blood inflammatory monocytes and exhibit phenotypes and functions that are distinct from mammary TRMs. Importantly, the terminal differentiation of these TAMs from monocytes is CSL/RBP-jκ-dependent, indicating that the canonical Notch signaling pathway plays a vital role in TAM differentiation ([@B14]). Therefore, at least for TAMs in this breast cancer model, Notch signaling plays both an extrinsic role, i.e., regulating the production of recruiting factors by tumor cells, and an intrinsic role, i.e., regulating the differentiation of TAMs. Whether TAMs associated with other tumor types also require CSL/RBP-jκ for their differentiation or function is still an open question.

Notch Signaling in Anti-Tumor Responses of TAMs {#S1-6}
-----------------------------------------------

Forced activation of the Notch receptor in TAMs in a Lewis lung carcinoma cell (LCC) model of cancer was shown to repress tumor-promoting activity by enhancing the anti-tumor phenotype and suppressing the pro-tumor phenotype. The mechanism of anti-tumor activity is reported to be mediated in part by microRNAs (miRNAs) ([@B50]). miRNAs are small regulatory non-coding RNAs of 21--22 nt that play important roles in regulating gene expression through post-transcriptional silencing of targets mRNAs. miRNAs play important roles in the activation and effector function of macrophages in TAMs by regulating their target genes and signaling pathway ([@B51]). In the LCC model, miR-152a, which is under regulation by Notch signaling, targets factor-inhibiting hypoxia 1 and IRF4, a transcription factor involved in M(IL-4) activation, to enhance the anti-tumor phenotype ([@B52]). In addition, another miRNA downstream of Notch signaling, miR-148a-3p, also helps to skew the activation of macrophages toward the anti-tumor phenotype by targeting the PTEN/Akt pathway and activation of the NF-κB pathway ([@B53]). This observation is consistent with the role of Notch signaling in favoring anti-tumor macrophage activation, and by forced activation of the Notch signaling pathway, these processes can result in the suppression of tumor growth.

Targeted deletion of *Rbpj* in macrophages resulted in reduced activity of CD8^+^ T cells by diminishing the cytotoxic activity against tumor cells in a B16 cell melanoma model ([@B17]), suggesting that the cross-talk between TAMs and CTLs is crucial for the anti-tumor immune response, and Notch signaling plays an important role in eliciting the anti-tumor activity of CTL. Moreover, activation of Notch signaling in macrophages was demonstrated to increase the CD8^+^ T cell population infiltrating the tumor site in the LCC model ([@B50]). These data indicate the ability of Notch signaling in TAMs to increase anti-tumor activity directly as pro-inflammatory macrophages or indirectly *via* cytotoxic T cells.

With the use of the opposite approach, manipulating canonical Notch signaling in TAMs in a mouse model of cancer was clearly demonstrated to be able to control tumor growth. Targeted deletion of *Rbpj* in macrophages resulted in anti-inflammatory phenotypes under pro-inflammatory inducers (such as LPS), and these macrophages lost the ability to control tumor growth ([@B17]). Therefore, if the Notch signaling pathway is dampened in TAMs, this dampening probably results in TAMs shifting toward an anti-inflammatory-like phenotype and helping tumor growth. One caveat is that this study employed *in vitro-*activated macrophages mixed with a tumor cell line that was administered to mice. Whether switching the Notch signaling on or off in TAMs after differentiation in the tumor influences the anti-tumor immunity remains an open question.

Contradictory to the studies described above, several reports have indicated that activation of Notch signaling supports anti-inflammatory phenotypes of macrophages and possibly favors TAMs ([@B27], [@B54]). A study in breast cancer patients who exhibited resistance to aromatase inhibitor treatment showed higher expression of Jagged1 in the tumor and an increasing density of anti-inflammatory TAM infiltration in breast cancer tissue compared to that in control ([@B42]). This study indirectly suggests that Jagged1 on cancer cells may drive TAMs into pro-tumor phenotype by activating Notch signaling in TAMs. These contradictory reports on Notch signaling in TAMs imply that the difference in TAM phenotype possibly depends on the tumor microenvironment and types of tumor, and this need to be taken into consideration. In addition, different Notch ligands may activate Notch signaling in different ways, and this may impact the phenotypes of TAMs.

TAMs, Tumor Angiogenesis, and Notch Signaling {#S1-7}
---------------------------------------------

Angiogenesis requires contact between macrophages and endothelial cells together with cytokines and angiogenic molecules. Inflammatory macrophages, including TAMs, are involved in angiogenesis based on the expression of cytokines, such as TNF-α and IL-6, and angiogenic factors, such as vascular endothelial growth factor (VEGF) ([@B5]). Because Notch signaling, directly or indirectly, regulates the expression of genes involved in angiogenesis, such as VEGFR and EphrinB2 ([@B55]), Notch signaling in TAMs may regulate tumor angiogenesis. In retinal choroidal neovascularization (CNV), the deletion of *Rbpj* in myeloid cells results in the inhibition of the inflammatory response in the retina and choroid after injury. This inhibited inflammatory response is accompanied by suppression of VEGF and TNF-α production and CNV development in the choroid ([@B56]). Moreover, Notch1-expressing macrophages interact with two Dll4-expressing sprouts of endothelial cells, leading to the activation of Notch signaling in macrophages. This interaction regulates the function of macrophages during vessel anastomosis in retina angiogenesis ([@B57]). Loss of Notch1 in myeloid lineage cells reduces microglia recruitment and results in abnormal angiogenesis ([@B58]).

Vascular cell adhesion molecule (VCAM) 1 is highly expressed in TAMs, whereas loss of VCAM1 in macrophages reduces the number of hematopoietic stem cells in the spleen and the inflammation in atherosclerosis due to an inability of macrophages to attach to vascular endothelial cells ([@B59]). Although little is known about the role of Notch signaling in the regulation of VCAM1 expression in macrophages, lung endothelial cells express high levels of VCAM1, and increased numbers of TAMs have been observed in lung cancer tissue compared to that in control. Endothelial cells were reported to undergo cellular senescence after implantation of tumor cells expressing Notch ligands (Dll4 and Jagged1), suggesting that VCAM1 expression in endothelial cells is under the regulation by Notch signaling and, together with Notch activation, required for TAM localization ([@B60]). VCAM1 expression in endothelial cells is under regulation of the Notch signaling pathway even in the absence of inflammatory cytokines. However, in the presence of IL-1β, VCAM1 expression in endothelial cells is greatly enhanced in a Notch-dependent manner ([@B61]). These studies suggest that endothelial VCAM1 is important for the survival of TAMs in the tumor microenvironment. However, this interaction through VCAM1 may be bidirectional because VCAM1 is also highly expressed in TAMs, suggesting that it may play an important role in the survival of endothelial cells as well. Blood vessel endothelial cells have also been found to play a role in TAM differentiation. A recent study demonstrated that Dll1 expressed by endothelial cells lining the blood vessels in mice induced conversion of Ly6C^hi^ to Ly6C^lo^ monocytes in a Notch2-dependent manner ([@B62]). This study was the first to demonstrate that the Notch ligand Dll1 in the blood vessel can induce phenotypic changes in monocytes through the Notch2 receptor under steady-state conditions.

The Role of Notch-Dependent TAMs in Supporting Tumor Growth and Immune Suppression {#S1-8}
----------------------------------------------------------------------------------

As described above, TAMs can directly support tumor growth by secreting factors, such as TGFβ ([@B48]). TAMs also affect the overall anti-tumor immunity mounted by other immune cells, such as T lymphocytes, in tumor sites by dampening the immune functions. Arginase 1, an arginine-degrading enzyme produced by M(IL-4), can suppress CTL activity ([@B63]). Recently, anti-inflammatory macrophage-like (CD206^+^ MHC II^low^ or ^negative^), but not pro-inflammatory macrophage-like (CD206^−^ MHCII^hi^) TAMs have been reported to express PD1 in both a mouse model and in human cancers over time with disease progression ([@B37]). The so-called immune checkpoint inhibitor is used to block this PD1-PD-L1 interaction and trigger a vigorous host immune response against the tumor. Interestingly, blocking this interaction results in increasing phagocytosis by macrophages and a reduction in tumor growth in mouse models of cancer ([@B37]). Although there is no evidence linking Notch signaling and PD1 in TAMs, there is a report indicating that canonical Notch signaling regulates the expression of PD1 in activated CD8^+^ T cells ([@B64]). Cancer-associated fibroblasts (CAFs) are indicated as accomplices in malignant cancers ([@B38]). Because CAFs and TAMs are reported to collaborate *via* cell--cell interaction in promoting tumor progression ([@B65]), it is possible that Notch signaling may contribute in the cross-talk between the two cell types. Taken together, these observations suggest that Notch signaling may be involved in regulating this immune suppression mechanism in TAMs *via* an immune checkpoint inhibitor.

Challenges and Potential for Manipulating Notch Signaling in TAMs for Therapy {#S1-9}
-----------------------------------------------------------------------------

Notch signaling clearly plays important roles in TAMs, either to promote or suppress tumor growth. Therefore, Notch signaling in TAMs can be a drug target for manipulating host anti-cancer immunity. If Notch signaling in TAMs is pro-tumoral, suppressing it would benefit the host. In contrast, if TAMs require Notch signaling to become more inflammatory anti-tumor macrophages, it needs to be stimulated. Various types of gamma-secretase inhibitor that is a pan-Notch signaling inhibitor are often used to suppress Notch signaling in cancer clinical trials ([@B66]). Unfortunately, this inhibitor has off-target effect and is highly toxic if applied systemically. Therefore, designing a method that specifically inhibits Notch signaling in TAMs is desirable. One approach is to use a stapled peptide derived from part of mastermind-like protein that interferes with canonical Notch signaling. If coupled with a TAM-specific delivery system, this peptide could specifically inhibit Notch signaling in TAMs ([@B67], [@B68]). Antibody-based specific antibody blocking has also been investigated for targeting the ligand-binding domain or the negative regulatory region of Notch receptors ([@B69]). To activate Notch signaling to favor inflammatory macrophages, an activating antibody that mimics ligand binding may be used. In any case, an intelligent method that targets TAMs is required to minimize the side effects.

Remaining Unresolved Questions and Future Directions {#S1-10}
----------------------------------------------------

Notch signaling in macrophages clearly affects their biological functions both directly and indirectly. Notch signaling also affects TAMs and functions in monocyte recruitment, tumor-mediated training, and angiogenesis. Notch signaling in TAMs is, therefore, an attractive signal to manipulate to promote anti-tumor immunity. Macrophages have been reported to be epigenetically modified by stimuli that contribute to "trained immunity" and "tolerance," at least *in vitro* ([@B70]). If the manipulation of macrophage polarization of TAMs through Notch signaling is to be considered as an alternative for cancer treatment, we must ask whether the epigenetic marks on TAMs imprinted by the tumor microenvironment, created by cancer cells, can be reversed or erased so that TAMs could act to benefit the host.
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